Barbara Bosch1, Kris De Boeck2. 1. Department of Paediatric Pulmonology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. barbara.bosch@uzleuven.be. 2. Department of Paediatric Pulmonology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. christiane.deboeck@uzleuven.be.
Abstract
After 25 years of intensive search, there is not yet a cure for cystic fibrosis (CF). However, the quest has led to major breakthroughs in understanding the basic disease defect and defining strategies to correct it. The first cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been introduced in clinic. Some show an impressive clinical benefit, like the potentiator ivacaftor for the 4% of patients with a class III defect. Others offer at present only a limited benefit, like the combination corrector lumacaftor plus potentiator ivacaftor for subjects homozygous for F508del. These findings prove that the basic defect in CF can be modified and hold the promise that one day CF will no longer be a life-shortening disease. CONCLUSION: This review updates the clinician on recent achievements as well as on the CF research pipeline. WHAT IS KNOWN: Cystic fibrosis (CF) is a common and life-shortening disease that currently cannot be cured. However, for each of the six CF mutation classes, disease-modifying drugs are under way. WHAT IS NEW: This review is a concise update for the clinician on new drugs that reached the CF clinical pipeline. The research strategies in CF have become a paradigm for clinical trials in other inherited diseases.
After 25 years of intensive search, there is not yet a cure for cystic fibrosis (CF). However, the quest has led to major breakthroughs in understanding the basic disease defect and defining strategies to correct it. The first cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been introduced in clinic. Some show an impressive clinical benefit, like the potentiator ivacaftor for the 4% of patients with a class III defect. Others offer at present only a limited benefit, like the combination corrector lumacaftor plus potentiator ivacaftor for subjects homozygous for F508del. These findings prove that the basic defect in CF can be modified and hold the promise that one day CF will no longer be a life-shortening disease. CONCLUSION: This review updates the clinician on recent achievements as well as on the CF research pipeline. WHAT IS KNOWN: Cystic fibrosis (CF) is a common and life-shortening disease that currently cannot be cured. However, for each of the six CF mutation classes, disease-modifying drugs are under way. WHAT IS NEW: This review is a concise update for the clinician on new drugs that reached the CF clinical pipeline. The research strategies in CF have become a paradigm for clinical trials in other inherited diseases.
Authors: Maria Fernanda Montiel-Gonzalez; Isabel Vallecillo-Viejo; Guillermo A Yudowski; Joshua J C Rosenthal Journal: Proc Natl Acad Sci U S A Date: 2013-10-09 Impact factor: 11.205
Authors: Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle Journal: N Engl J Med Date: 2015-05-17 Impact factor: 91.245
Authors: Drucy Borowitz; Barry Lubarsky; Michael Wilschanski; Anne Munck; Daniel Gelfond; Frank Bodewes; Sarah Jane Schwarzenberg Journal: Dig Dis Sci Date: 2015-08-07 Impact factor: 3.199
Authors: J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Tsukasa Okiyoneda; Guido Veit; Johanna F Dekkers; Miklos Bagdany; Naoto Soya; Haijin Xu; Ariel Roldan; Alan S Verkman; Mark Kurth; Agnes Simon; Tamas Hegedus; Jeffrey M Beekman; Gergely L Lukacs Journal: Nat Chem Biol Date: 2013-05-12 Impact factor: 15.040
Authors: Eitan Kerem; Michael W Konstan; Kris De Boeck; Frank J Accurso; Isabelle Sermet-Gaudelus; Michael Wilschanski; J Stuart Elborn; Paola Melotti; Inez Bronsveld; Isabelle Fajac; Anne Malfroot; Daniel B Rosenbluth; Patricia A Walker; Susanna A McColley; Christiane Knoop; Serena Quattrucci; Ernst Rietschel; Pamela L Zeitlin; Jay Barth; Gary L Elfring; Ellen M Welch; Arthur Branstrom; Robert J Spiegel; Stuart W Peltz; Temitayo Ajayi; Steven M Rowe Journal: Lancet Respir Med Date: 2014-05-15 Impact factor: 30.700
Authors: Hong Yu Ren; Diane E Grove; Oxana De La Rosa; Scott A Houck; Pattarawut Sopha; Fredrick Van Goor; Beth J Hoffman; Douglas M Cyr Journal: Mol Biol Cell Date: 2013-08-07 Impact factor: 4.138
Authors: Chiara De Santi; Elena Fernández Fernández; Rachel Gaul; Sebastian Vencken; Arlene Glasgow; Irene K Oglesby; Killian Hurley; Finn Hawkins; Nilay Mitash; Fangping Mu; Rana Raoof; David C Henshall; Meritxell B Cutrona; Jeremy C Simpson; Brian J Harvey; Barry Linnane; Paul McNally; Sally Ann Cryan; Ronan MacLoughlin; Agnieszka Swiatecka-Urban; Catherine M Greene Journal: Mol Ther Date: 2020-02-06 Impact factor: 11.454
Authors: Sachinkumar B Singh; Amanda J McLearn-Montz; Francesca Milavetz; Levi K Gates; Christopher Fox; Logan T Murry; Ashley Sabus; Harry S Porterfield; Anthony J Fischer Journal: Pediatr Pulmonol Date: 2019-04-22
Authors: J Stuart Elborn; Bonnie W Ramsey; Michael P Boyle; Michael W Konstan; Xiaohong Huang; Gautham Marigowda; David Waltz; Claire E Wainwright Journal: Lancet Respir Med Date: 2016-06-10 Impact factor: 30.700